27 results on '"Maurea, N"'
Search Results
2. 2312P SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
3. 2296P SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
4. 2260P Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
5. 2244P Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
6. 36P Short-term immune check-point inhibitor treatment reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and serum IL-1, IL-2 and IL-6 levels
7. 13P Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, methylglyoxal and leukotrienes-B4 levels
8. 15P The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR-α and NLRP3-related pathways
9. 14P Sacubitril-valsartan increases pAMPK and reduces NLRP3, MyD88, interleukin-6 and galectin-3 in short-term doxorubicin-treated mice improving longitudinal strain and ejection fraction
10. 27P Oxidized low-density lipoprotein induces cell dead and inflammation in cardiomyocytes exposed to nivolumab by TLR4/NF-κB and NLRP3/myd88 pathways
11. 6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways
12. 1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathway
13. 1944P Hyperglycemia increased nivolumab-induced cardiotoxicity, enhanced immunoresistance of ERɑ+, PR+, HER2- breast cancer cells modulating growth factors and NLRP3 expression
14. 1894P - Cardioprotective and anti-inflammatory effects of empagliflozin during treatment with doxorubicin: A cellular and preclinical study
15. 1306P - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor pembrolizumab and trastuzumab in preclinical models
16. 400P - LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model
17. 25P - Ranolazine partially blunts ado trastuzumab emtansine related cardiotoxicity
18. 24P - Cardiotoxic effects of the novel anti-ErbB2 agent ado trastuzumab emtansine
19. 811 Ranolazine reduces Trastuzumab toxicity in vitro and in vivo, when it is administered after anticancer treatment
20. 441 Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and waist-hip ratio in cancer patients
21. P127 Metabolic syndrome and breast cancer risk by molecular subtype
22. P059 Ranolazine administered after trastuzumab treatment prevents cardiotoxicity in mice
23. 165P - Ranolazine Before and During Trastuzumab Treatment, Prevents Cardiotoxicity in Mice
24. 166P - Doxorubicin-Cardiotoxicity is Blunted If Ranolazine is Administered After Doxorubicin Treatment, in Experimental Models
25. 1682P - Anthracycline-Induced Cardiotoxicity in Mice is Prevented by Late INa Inhibition with Ranolazine, With Improvement in Heart Function, Fibrosis and Apoptosis
26. P114 The anti-neoplastic ErbB2-antibody 2C4 produces left ventricular dysfunction in murine hearts
27. 1114 POSTER The Anticancer MTOR-inhibitor Temsirolimus Induces Cardiotoxicity in a Mouse Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.